Best Free Stock Screeners in 2026
This article compares software. It is not investment advice, and nothing here is a recommendation to buy or sell anything. What a screener does is filter a list; what you do with the list is your decision and ideally your licensed adviser's.
With that said, this is the most interesting rating spread we have found in any category. Most software comparisons produce four tools within two tenths of each other. Here the range runs from 2.7 to 4.8, on samples large enough that the gap is not noise.
The ratings
Aggregated by Toolradar across G2, Capterra and other platforms, checked 18 August 2026.
| Tool | Aggregated rating | Reviews |
|---|---|---|
| Koyfin | 4.8 | 135 |
| TradingView | 4.5 | 75 |
| Finviz | 3.4 | 28 |
| Stock Rover | 3.0 | 2 |
| Zacks | 2.7 | 168 |
Zacks carries the largest sample here and the lowest score. A 2.7 across 168 reviews is the worst-rated product we have published in any guide, and unlike most low scores in our articles it is not resting on a handful of angry reviews. We are not going to characterise why beyond what the data supports: go and read them before subscribing to anything.
Stock Rover's 3.0 comes from two reviews and should be ignored entirely. Finviz's 3.4 across 28 is weak evidence of a middling experience.
Koyfin's 4.8 across 135 is the strongest combination of score and sample in the table.
The prices, verified
All checked 18 August 2026.
| Tool | Free tier | First paid tier |
|---|---|---|
| TradingView | Free | paid plans available |
| Finviz | Free | Elite, 7-day free trial then paid |
| Zacks | Free | paid research subscriptions |
| Koyfin | Free, $0/month | Plus, $39/month |
| Stock Rover | — | Premium, contact sales |
Two of these deserve a flag rather than a number. Finviz's directory record lists the Elite tier as a 7-day free trial without a published ongoing price, and Stock Rover's tiers all read "contact us". We are not going to fill those gaps from memory. Check the current pricing pages directly.
Koyfin's $39 Plus tier is the clearest paid step in the category, rising to $79 for Premium and $209 for Advisor Core.
Koyfin
Koyfin is the best-rated tool here and the one that feels least like a screener and most like a terminal.
The free tier gives you fundamentals, charting, financial statements, estimates and a screener across global equities. What it is genuinely good at is comparison: pulling twenty companies side by side across the same twelve metrics and seeing the outliers immediately.
The paid tiers add history depth, more dashboards and export. Plus is $39 a month, which places it above every other paid option in this article that publishes a price.
4.8 across 135 reviews is a strong result on a respectable sample, and it is the only score in this table we would weight heavily.
TradingView
TradingView is the charting platform that happens to have a screener, and it is the most widely used tool in this article by a distance.
Its free tier covers the screener, the charts and a large public library of community-built indicators. The screener itself is competent rather than exceptional: good filters on price action and technical conditions, thinner on fundamentals than Koyfin.
Where it wins is everything around the screen. You filter to a list, click a symbol, and you are in the best charting interface in retail finance, with alerts you can set in a few clicks.
4.5 across 75 reviews.
Finviz
Finviz is the fastest free screener on the web and its interface has barely changed in a decade, which its users consider a feature.
The free version handles US equities with a dense grid of filters, a heatmap that has become the standard way people look at a market day, and results that load instantly. For a quick screen with no account, nothing here is faster.
Its 3.4 rating across 28 reviews is the middle of this table on thin evidence. The known limitations of the free tier are real: delayed data, US coverage only, and a screener that resets more often than you would like.
Stock Rover
Stock Rover is the fundamentals-heavy option, aimed at long-horizon investors who want ten years of financials and screening on metrics most tools do not carry.
Its pricing is not published in the directory record and its 3.0 rests on two reviews. We have no basis to rate it and are saying so rather than padding the article.
Zacks
Zacks is best known for its ranking system, which scores stocks on earnings estimate revisions, and its free tier gives access to those ranks.
Its 2.7 aggregated rating across 168 reviews is the lowest we have published anywhere. That is a large enough sample that it is not an accident, and it sits alongside a free tier that is genuinely useful. Both things are true at once, which is uncomfortable and worth stating plainly rather than resolving.
Our position: use the free ranks if you find them useful, read the reviews yourself before paying for anything, and treat the subscription decision as separate from the screener decision.
What free actually limits
Across all five, free tiers ration the same four things, and knowing which one binds you is more useful than a ranking.
Data delay. Free tiers are typically delayed rather than real-time. For anyone screening weekly this is irrelevant. For anyone screening intraday it is disqualifying, and no amount of features compensates.
Market coverage. Finviz free is US-only. Koyfin's free tier is global. If you invest outside the US this single fact decides the article for you.
Saved screens and alerts. Nearly every free tier caps how many screens you can save and whether it will tell you when something matches. This is the limit most people hit first, and it is the one that most reliably converts them to paying.
History depth. Free tiers show recent fundamentals. Ten years of financials is a paid feature almost everywhere, which matters for exactly one type of user and not at all for the rest.
Picking one
Global coverage and comparison work: Koyfin's free tier, which is the most capable free product here.
Charting is the real job: TradingView.
A fast US screen with no account: Finviz.
And on the ratings, the useful lesson is the opposite of the usual one. In most of our guides the scores cluster so tightly that they carry no information. Here they spread across two full points on real samples, and the spread is the most informative thing in the article. When ratings actually diverge, read them.
A screener is a filter, not an answer
The most common way people get hurt by these tools has nothing to do with which one they picked.
A screener returns the stocks that match your criteria. It does not return the stocks that are good, and the difference is the entire discipline. Any set of filters, applied to thousands of companies, will produce a list. The list will look meaningful because it is short and specific. That feeling is manufactured by the sorting, not by the companies.
Two practical consequences follow.
The more filters you add, the more confident and the more arbitrary the result. Screening on eight conditions across a universe of 5,000 companies will leave you six names. Those six are not the best six, they are the six that survived an arbitrary intersection, and changing one threshold by a tenth would have produced six different ones. Backtesting a screen against past data compounds this rather than fixing it, because you are choosing the filters after seeing which ones would have worked.
Free data is late data, and late data changes what a screen means. A filter on price is measuring a price from fifteen minutes ago on most free tiers, and a filter on fundamentals is measuring the last reported quarter, which can be three months stale. Neither matters for a long-horizon screen. Both matter enormously for anything else, and the tool will not warn you.
None of that is an argument against screeners. It is an argument for treating the output as a reading list rather than a shortlist, which is how the people who use these tools well have always used them.
If you want a view on what to actually do with the names, that is a conversation for a licensed financial adviser. We compare software.
Related: free corporate cards, free AI expense management tools and free AI research assistants.
